Location History:
- Funabashi, JP (1998)
- Kawasaki, JP (1994 - 2013)
- Tokyo, JP (1999 - 2019)
Company Filing History:
5 out of 228 
3 out of 28,546 
3 out of 3 
Years Active: 1994-2019
Title: The Innovative Contributions of Tsuyoshi Harada
Introduction: Tsuyoshi Harada, an accomplished inventor based in Tokyo, Japan, has made significant strides in the field of medical treatments. With a total of 13 patents to his name, Harada's work primarily focuses on advancements in treatments for fatty liver disorders, particularly non-alcoholic steatohepatitis.
Latest Patents: Among Harada's latest innovations are his patents related to compositions and methods for treating non-alcoholic steatohepatitis. One notable patent outlines a method for treating fatty liver disorders in subjects, which includes selecting individuals who may be non-diabetic, pre-diabetic, mildly diabetic, or have normal biliary tract function. The method involves administering a therapeutically effective amount of a pharmaceutical composition containing ethyl eicosapentanoate (EPA-E), with the composition potentially comprising at least 40% by weight of total fatty acids and their derivatives. Furthermore, his patents include other compositions and methods that specifically utilize ethyl icosapentate for the treatment of non-alcoholic steatohepatitis (NASH).
Career Highlights: Tsuyoshi Harada has worked with prominent companies such as Mochida Pharmaceutical Co., Ltd. and Ricoh Company, Ltd. His tenure at these organizations has significantly contributed to the advancement of pharmaceutical technologies and innovative treatments for metabolic disorders.
Collaborations: Harada's collaborative efforts include working alongside esteemed colleagues such as Kiyoshi Mizuguchi and Koji Tanaka. These partnerships have fostered a dynamic environment for developing new therapeutic approaches and enhancing existing treatments.
Conclusion: With an impressive portfolio of patents and a dedication to improving health outcomes, Tsuyoshi Harada's contributions to medical science are noteworthy. His innovative methods for treating non-alcoholic steatohepatitis underline the potential for impactful advancements in the treatment of fatty liver diseases.